PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs SRPT |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 0.17 | 11.7 | 69.3% | — |
| KRYS | Krystal Biotech, Inc. | 0.31 | 38.7 | 126.9% | — |
| BMRN | BioMarin Pharmaceutical Inc. | 5.62 | 151.3 | 26.9% | — |